Exhibit 99

		Contact:		Claire M. Gulmi
				Executive Vice President and
				Chief Financial Officer
				(615) 665-1283

AMSURG ANNOUNCES SECOND-QUARTER NET EARNINGS
FROM CONTINUING OPERATIONS OF $0.41 PER DILUTED SHARE

RESULTS INCLUDE 1% GROWTH IN SAME-CENTER REVENUE AND TRANSACTION
COSTS OF $0.02 PER DILUTED SHARE
AFFIRMS 2011 FINANCIAL GUIDANCE

NASHVILLE, Tenn. — (July 21, 2011) — Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp. (NASDAQ: AMSG), today announced financial results for the second quarter ended June 30, 2011. Revenues for the quarter rose 7% to $188,730,000 from $175,698,000 for the second quarter of 2010. Net earnings from continuing operations attributable to AmSurg common shareholders were $12,758,000, or $0.41 per diluted share, for the second quarter of 2011 compared with $12,716,000, or $0.41 per diluted share, for the second quarter of 2010. As anticipated, the results for the second quarter of 2011 included an incremental negative impact of $0.01 per diluted share from the revision of the Medicare payment system for ASCs and $0.03 per diluted share from the higher interest costs related to the refinancing of the Company’s credit facility in May 2010 and a higher effective tax rate. In addition, these results include acquisition transaction costs of $0.02 per diluted share related to the Company’s definitive merger agreement with National Surgical Care, announced in April 2011.

     Revenues for the first six months of 2011 increased 7% to $367,600,000 from $343,725,000 for the same period in 2010. Net earnings from continuing operations attributable to AmSurg common shareholders were $24,433,000, or $0.78 per diluted share, for the first half of 2011 compared with $25,117,000, or $0.82 per diluted share, for first six months of 2010. The results for the first six months of 2011 included an incremental negative impact of $0.02 per diluted share from the revision of the Medicare payment system for ASCs, $0.07 per diluted share from the higher interest costs related to the credit facility refinancing and a higher effective tax rate, and $0.02 per diluted share for acquisition transaction costs.

     “We are pleased to see modest strengthening in our comparable-quarter performance for the second quarter versus the first quarter, but our procedure volume, revenues, margins and earnings continue to be negatively affected by the weak national economy and high unemployment. Our revenue growth for the second quarter, which reflected a 7% increase in procedures, was produced largely from the expansion of our centers in operation during the previous year, to 208 at the end of the second quarter of 2011 from 197 at the same time in 2010. We also benefited from a 1% increase in same-center revenue for the comparable quarters. EBITDA less noncontrolling interests was 16.7% of revenue for the second quarter of 2011,

-MORE-

AMSG Reports Second-Quarter Results
Page 2
July 21, 2011

which included a negative impact of approximately 60 basis points from the NSC transaction costs, compared with 17.5% for the second quarter last year.

     “We added five new centers during the second quarter, comprised of four acquisitions and the opening of a de novo center. The four acquisitions were among the seven centers we had expected to acquire by year-end 2010. We acquired another one of those centers in the first quarter of 2011, have completed the acquisition of the sixth of those centers since the end of the second quarter and are no longer pursuing the acquisition of the seventh center. We ended the second quarter of 2011 with four centers under letter of intent, including the one center since acquired in the third quarter, and with another center under development, which we expect to open in 2012.

     “Net cash flows from operating activities were $61.7 million for the second quarter of 2011 compared with $52.6 million for the second quarter of 2010. Excluding distributions to noncontrolling interests, net cash flows from operations were $26.2 million for the latest quarter compared with $17.2 million for the second quarter of 2010, which drove an 11% increase in net cash flows from operations excluding distributions to noncontrolling interests for the first six months of 2011. At the end of the second quarter, the ratio of total debt to trailing 12 months EBITDA was 2.4, we had cash and cash equivalents of $33.0 million and our availability under our revolving credit facility was $252 million.

     “On April 7, 2011, we announced a definitive agreement to acquire National Surgical Care (NSC), which we originally expected to complete before the end of the second quarter, subject to normal closing conditions, regulatory approvals and clearance under the Hart-Scott-Rodino Act. We continue to work with NSC toward meeting the conditions to close this transaction. We will incorporate the specific impact of the transaction into our guidance for 2011 only after the transaction is complete. As a result, today, we affirm our existing guidance for 2011 revenue and net earnings from continuing operations per diluted share attributable to common shareholders, and we establish our guidance for the third quarter of 2011, neither of which includes any future expected impact from the NSC transaction:

	•		Revenues in a range of $740 million to $770 million for 2011.
	•		Same-center revenues revised to a new range of 0% to 1% for 2011 from the previous range of 0% to a negative 1%.
	•		The addition of 18 to 20 new centers for the year, not including the NSC transaction.
	•		Net cash flow provided by operating activities, less distributions to noncontrolling interests, in a range of $90 million to $95 million.
	•		Net earnings from continuing operations per diluted share attributable to common shareholders for 2011 in a range of $1.64 to $1.68, which includes a negative $0.05 impact from the effect of the revised Medicare payment system, a negative $0.07 impact from higher interest costs related to the refinancing of our revolving credit facility and the higher effective tax rate, and acquisition transaction costs incurred in the second quarter of $0.02 per diluted share related to the NSC transaction.
	•		Net earnings from continuing operations per diluted share attributable to common shareholders for the third quarter of 2011 in a range of $0.42 to $0.44 per diluted share, including a negative $0.01 impact from the effect of the revised Medicare payment system revision.”

-MORE-

AMSG Reports Second-Quarter Results
Page 3
July 21, 2011

     The information contained in the preceding paragraphs is forward-looking information, and the attainment of these targets is dependent not only on AmSurg’s achievement of itsassumptions discussed above, but also on the risks and uncertainties listed below that could cause actual results, performance or developments to differ materially from those expressed or implied by this forward-looking information.

     Mr. Holden concluded, “We are encouraged by the positive same-center revenues achieved for the second quarter of 2011, but we remain cautious about the sustainability of this improvement in the second half of the year due to the weak economic environment and continuing high unemployment. Moving into 2012, our same-center performance will benefit from the completion of reductions in Medicare rate reimbursement in 2011, with no scheduled reduction in Medicare rates for 2012 for the first time in four years. In addition, we have now cycled the negative comparable-quarter impact of our refinancing at the end of May 2010. We continue to expect the full-year financial impact in 2012 of centers added in 2011 will be significantly more beneficial than their impact in 2011.

     “A number of compelling factors also support our longer-term growth prospects, including the aging U.S. population, substantially improved healthcare access for previously uninsured and underserved populations, and ongoing healthcare technology advances that enable additional surgical procedures to migrate from inpatient to outpatient venues. Due in part to the national concern over healthcare quality and the relentless rise in healthcare costs, there is also growing recognition among payers that freestanding ASCs provide high quality in the most affordable modality for many surgical procedures and that a substantial majority of these procedures are still being performed in much more expensive venues. As the country’s leading operator of freestanding ambulatory surgery centers, we are confident AmSurg is favorably positioned to leverage these strong industry dynamics to drive long-term growth in earnings and shareholder value.”

     AmSurg Corp. will hold a conference call to discuss this release today at 5:00 p.m. Eastern time. Investors will have the opportunity to listen to the conference call over the Internet by going to www.amsurg.com and clicking “Investors” or by going to www.earnings.com at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available at these sites shortly after the call and continue for 30 days.

     This press release contains forward-looking statements. These statements, which have been included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties. Investors are hereby cautioned that these statements may be affected by the important factors, among others, set forth in AmSurg’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and other filings with the Securities and Exchange Commission, including the following risks: the risk that payments from third-party payors, including government healthcare programs, may decrease or not increase as the Company’s costs increase; adverse developments affecting the medical practices of the Company’s physician partners; the Company’s ability to maintain favorable relations with its physician partners; the Company’s ability to acquire and develop additional surgery centers on favorable terms; the Company’s ability to grow revenues by increasing procedure volume while maintaining its operating margins and profitability at its existing centers; the Company’s ability

-MORE-

AMSG Reports Second-Quarter Results
Page 4
July 21, 2011

to manage the growth in its business; the Company’s ability to obtain sufficient capital resources to complete acquisitions and develop new surgery centers; the Company’s ability physician partners, managed care contracts, patients and strategic relationships; adverse weather and other factors beyond the Company’s control that may affect the Company’s surgery centers; adverse impacts on the Company’s business associated with current and future economic conditions; the Company’s failure to comply with applicable laws and regulations; the risk of changes in legislation, regulations or regulatory interpretations that may negatively affect the Company; the risk of becoming subject to federal and state investigation; the risk from an unpredictable impact of the Health Reform Law; the risk of regulatory changes that may obligate the Company to buy out interests of physicians who are minority owners of its surgery centers; potential liabilities associated with the Company’s status as a general partner of limited partnerships; liabilities for claims brought against our facilities; the Company’s legal responsibility to minority owners of its surgery centers, which may conflict with its interests and prevent it from acting solely in its best interests; risks associated with the potential write-off of the impaired portion of intangible assets; and potential liability relating to the tax deductibility of goodwill. Consequently, actual results, performance or developments may differ materially from the forward-looking statements included above. AmSurg disclaims any intent or obligation to update these forward-looking statements.

     AmSurg Corp. acquires, develops and operates ambulatory surgery centers in partnership with physician practice groups throughout the United States. At June 30, 2011, AmSurg owned a majority interest in 208 continuing centers in operation and had one center under development.

-MORE-

AMSG Reports Second-Quarter Results
Page 5
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

		For the Three Months								For the Six Months
		Ended June 30,								Ended June 30,
Statement of Earnings Data:		2011				2010				2011				2010
Revenues		$	188,730			$	175,698			$	367,600			$	343,725
Operating expenses:
Salaries and benefits			57,492				51,451				113,102				102,244
Supply cost			24,254				22,701				47,035				44,768
Other operating expenses			40,663				37,923				78,669				74,621
Depreciation and amortization			6,161				5,856				12,102				11,523
Total operating expenses			128,570				117,931				250,908				233,156
Operating income			60,160				57,767				116,692				110,569
Interest expense			3,633				3,163				7,576				5,031
Earnings from continuing operations before income taxes			56,527				54,604				109,116				105,538
Income tax expense			8,949				9,088				17,263				17,521
Net earnings from continuing operations			47,578				45,516				91,853				88,017
Discontinued operations:
(Loss) earnings from operations of discontinued interests in surgery centers, net of income tax			(117	)			1,112				417				2,123
Loss on disposal of discontinued interests in surgery centers, net of income tax			(1,084	)			—				(1,265	)			—
Net (loss) earnings from discontinued operations			(1,201	)			1,112				(848	)			2,123
Net earnings			46,377				46,628				91,005				90,140
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations			34,820				32,800				67,420				62,900
Net (loss) earnings from discontinued operations			(73	)			686				262				1,401
Total net earnings attributable to noncontrolling interests			34,747				33,486				67,682				64,301
Net earnings attributable to AmSurg Corp. common shareholders		$	11,630			$	13,142			$	23,323			$	25,839
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		$	12,758			$	12,716			$	24,433			$	25,117
Discontinued operations, net of income tax			(1,128	)			426				(1,110	)			722
Net earnings attributable to AmSurg Corp. common shareholders		$	11,630			$	13,142			$	23,323			$	25,839
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.42			$	0.42			$	0.80			$	0.83
Net (loss) earnings from discontinued operations attributable to AmSurg Corp. common shareholders			(0.04	)			0.01				(0.04	)			0.02
Net earnings attributable to AmSurg Corp. common shareholders		$	0.38			$	0.43			$	0.77			$	0.85
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.41			$	0.41			$	0.78			$	0.82
Net (loss) earnings from discontinued operations attributable to AmSurg Corp. common shareholders			(0.04	)			0.01				(0.04	)			0.02
Net earnings attributable to AmSurg Corp. common shareholders		$	0.37			$	0.43			$	0.75			$	0.84
Weighted average number of shares and share equivalents (000’s):
Basic			30,415				30,239				30,418				30,226
Diluted			31,335				30,655				31,180				30,685

AMSG Reports Second-Quarter Results
Page 6
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands, except per share amounts)

		For the Three Months								For the Six Months
		Ended June 30,								Ended June 30,
Operating Data:		2011				2010				2011				2010
Continuing centers in operation at end of period			208				197				208				197
Average number of continuing centers in operation			208				197				205				196
New centers added during the period			5				1				6				2
Centers discontinued during the period			—				—				2				—
Centers under development/not opened at end of period			1				1				1				1
Centers under letter of intent at end of period			4				6				4				6
Average revenue per center		$	909			$	894			$	1,791			$	1,755
Same center revenues increase (decrease)			1	%			(2	%)			1	%			(2	%)
Procedures performed during the period			340,049				316,962				660,076				617,672
Income tax expense attributable to noncontrolling interests		$	175			$	213			$	304			$	399
Reconciliation of net earnings to EBITDA (1):
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	12,758			$	12,716			$	24,433			$	25,117
Add: income tax expense			8,949				9,088				17,263				17,521
Add: interest expense, net			3,633				3,163				7,576				5,031
Add: depreciation and amortization			6,161				5,856				12,102				11,523
EBITDA		$	31,501			$	30,823			$	61,374			$	59,192

AMSG Reports Second-Quarter Results
Page 7
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands)

		June 30,				December 31,
Balance Sheet Data:		2011				2010
Assets
Current assets:
Cash and cash equivalents		$	32,954			$	34,147
Accounts receivable, net of allowance of $13,719 and $13,070, respectively			70,848				67,617
Supplies inventory			10,363				10,157
Deferred income taxes			2,073				1,509
Prepaid and other current assets			16,281				18,660
Current assets held for sale			264				866
Total current assets			132,783				132,956
Property and equipment, net			121,707				119,167
Goodwill			964,970				894,497
Intangible assets, net			15,921				11,361
Long-term assets held for sale			87				7,897
Total assets		$	1,235,468			$	1,165,878
Liabilities and Equity
Current liabilities:
Current portion of long-term debt		$	7,826			$	6,648
Accounts payable			11,485				15,291
Accrued salaries and benefits			18,191				17,952
Other accrued liabilities			4,158				3,136
Current liabilities held for sale			66				536
Total current liabilities			41,726				43,563
Long-term debt			293,070				283,215
Deferred income taxes			102,773				90,089
Other long-term liabilities			20,688				24,404
Noncontrolling interests — redeemable			165,688				147,740
Equity:
Common stock, no par value 70,000,000 shares authorized, 31,282,439 and 31,039,770 shares outstanding, respectively			171,342				171,522
Retained earnings			416,384				393,061
Accumulated other comprehensive loss, net of income taxes			—				(515	)
Total AmSurg Corp. equity			587,726				564,068
Noncontrolling interests — non-redeemable			23,797				12,799
Total equity			611,523				576,867
Total liabilities and equity		$	1,235,468			$	1,165,878

AMSG Reports Second-Quarter Results
Page 8
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands)

		For the Three Months								For the Six Months
		Ended June 30,								Ended June 30,
Statement of Cash Flow Data:		2011				2010				2011				2010
Cash flows from operating activities:
Net earnings		$	46,377			$	46,628			$	91,005			$	90,140
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization			6,156				5,856				12,102				11,523
Net loss on sale of long-lived assets			(465	)			—				(363	)			—
Share-based compensation			1,578				1,309				3,171				2,540
Excess tax benefit from share-based compensation			(61	)			(23	)			(463	)			(69	)
Deferred income taxes			5,814				4,339				11,460				8,045
Increase (decrease) in cash and cash equivalents, net of effects of acquisition and dispositions, due to changes in:
Accounts receivable, net			(290	)			(1,916	)			(1,534	)			(2,882	)
Supplies inventory			141				207				67				225
Prepaid and other current assets			1,144				760				2,506				1,895
Accounts payable			(1,590	)			(1,120	)			(3,737	)			(2,773	)
Accrued expenses and other liabilities			2,666				(3,908	)			(1,866	)			(2,385	)
Other, net			275				428				677				625
Net cash flows provided by operating activities			61,745				52,560				113,025				106,884
Cash flows from investing activities:
Acquisition of interest in surgery centers and related transactions			(41,979	)			(5,526	)			(45,674	)			(33,201	)
Acquisition of property and equipment			(5,959	)			(4,021	)			(10,303	)			(7,531	)
Proceeds from the sale of interests in surgery centers			3				—				3,369				—
Net cash flows used in investing activities			(47,935	)			(9,547	)			(52,608	)			(40,732	)
Cash flows from financing activities:
Proceeds from long-term borrowings			57,364				103,068				72,984				139,689
Repayment on long-term borrowings			(40,076	)			(113,243	)			(64,852	)			(139,156	)
Distributions to noncontrolling interests			(35,497	)			(35,392	)			(67,360	)			(65,621	)
Proceeds from issuance of common stock upon exercise of stock options			891				246				4,628				542
Repurchase of common stock			—				—				(6,185	)			—
Capital contributions and ownership transactions by noncontrolling interests			675				3				698				(137	)
Excess tax benefit from share-based compensation			61				23				463				69
Financing cost incurred			(1,982	)			(4,377	)			(1,986	)			(4,402	)
Net cash flows used in financing activities			(18,564	)			(49,672	)			(61,610	)			(69,016	)
Net decrease in cash and cash equivalents			(4,754	)			(6,659	)			(1,193	)			(2,864	)
Cash and cash equivalents, beginning of period			37,708				33,172				34,147				29,377
Cash and cash equivalents, end of period		$	32,954			$	26,513			$	32,954			$	26,513

- MORE -

AMSG Reports Second-Quarter Results
Page 9
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

Presented below is certain statement of earnings and operating data for 2011 and 2010, which have been restated in order to present additional discontinued operations.

																						For the Year
		For the Three Months																				Ended
		March 31,				March 31,				June 30,				Sept. 30,				Dec. 31,				Dec. 31,
Statement of Earnings Data:		2011				2010				2010				2010				2010				2010
Revenues		$	178,870			$	168,027			$	175,698			$	176,343			$	183,371			$	703,439
Operating expenses:
Salaries and benefits			55,610				50,793				51,451				53,350				56,215				211,809
Supply cost			22,781				22,067				22,701				23,155				23,807				91,730
Other operating expenses			38,006				36,698				37,923				36,918				36,648				148,187
Depreciation and amortization			5,941				5,667				5,856				6,975				6,430				24,928
Total operating expenses			122,338				115,225				117,931				120,398				123,100				476,654
Operating income			56,532				52,802				57,767				55,945				60,271				226,785
Interest expense			3,943				1,868				3,163				4,040				4,415				13,486
Earnings from continuing operations before income taxes			52,589				50,934				54,604				51,905				55,856				213,299
Income tax expense			8,314				8,433				9,088				7,644				8,626				33,791
Net earnings from continuing operations			44,275				42,501				45,516				44,261				47,230				179,508
Net earnings (loss) from discontinued operations			353				1,011				1,112				874				(2,009	)			988
Net earnings			44,628				43,512				46,628				45,135				45,221				180,496
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations			32,600				30,100				32,800				31,417				34,047				128,364
Net earnings from discontinued operations			335				715				686				600				306				2,307
Total net earnings attributable to noncontrolling interests			32,935				30,815				33,486				32,017				34,353				130,671
Net earnings attributable to AmSurg Corp. common shareholders		$	11,693			$	12,697			$	13,142			$	13,118			$	10,868			$	49,825
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		$	11,675			$	12,402			$	12,716			$	12,844			$	13,183			$	51,145
Discontinued operations, net of income tax			18				295				426				274				(2,315	)			(1,320	)
Net earnings attributable to AmSurg Corp. common shareholders		$	11,693			$	12,697			$	13,142			$	13,118			$	10,868			$	49,825
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.38			$	0.41			$	0.42			$	0.42			$	0.43			$	1.69
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders			0.00				0.01				0.01				0.01				(0.08	)			(0.04	)
Net earnings attributable to AmSurg Corp. common shareholders		$	0.38			$	0.42			$	0.43			$	0.43			$	0.36			$	1.65
Earnings per share — diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.38			$	0.40			$	0.41			$	0.42			$	0.43			$	1.67
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders			0.00				0.01				0.01				0.01				(0.08	)			(0.04	)
Net earnings attributable to AmSurg Corp. common shareholders		$	0.38			$	0.41			$	0.43			$	0.43			$	0.35			$	1.62
Weighted average number of shares and share equivalents (000’s):
Basic			30,420				30,212				30,239				30,251				30,318				30,255
Diluted			31,024				30,716				30,655				30,620				30,763				30,689

- MORE -

AMSG Reports Second-Quarter Results
Page 10
July 21, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

Presented below is certain statement of earnings and operating data for 2011 and 2010, which have been restated in order to present additional discontinued operations.

																						For the Year
		For the Three Months																				Ended
		March 31,				March 31,				June 30,				Sept. 30,				Dec. 31,				Dec. 31,
Operating Data:		2011				2010				2010				2010				2010				2010
Procedures			320,027				300,710				316,962				319,870				330,045				1,267,587
Reconciliation of net earnings to EBITDA (1):
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	11,675			$	12,402			$	12,716			$	12,844			$	13,183			$	51,145
Add: income tax expense			8,314				8,433				9,088				7,644				8,626				33,791
Add: interest expense, net			3,943				1,868				3,163				4,040				4,415				13,486
Add: depreciation and amortization			5,941				5,667				5,856				6,975				6,430				24,928
EBITDA		$	29,873			$	28,370			$	30,823			$	31,503			$	32,654			$	123,350

- END -